IRIDEX Announces Approval of CYCLO G6™ Glaucoma Laser System in Korea > IRIDEX



MOUNTAIN VIEW, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the approval of its CYCLO G6™ Glaucoma Laser system by South Korea's Ministry of Food and Drug Safety (MFDS). Currently available in more than 50 countries, the CYCLO G6 treats patients diagnosed with a range of glaucoma disease states using the Company’s proprietary MicroPulse® technology and a family of single use probes.

“International expansion in the Asia-Pacific region remains a top priority for us and we believe that Korea represents an attractive market opportunity for our G6 technology,” said William M. Moore, President and Chief Executive Officer. “We set G6 approval in Korea as a key target for our 2018 expansion strategy and I am delighted to have reached this key milestone. Importantly, we have already started to garner feedback and support from key opinion leaders in the region and expect to leverage their support in our launch strategy.”

The CYCLO G6 platform is supported by a growing body of clinical evidence and extensive validation in the field for the treatment of glaucoma. Physicians worldwide have adopted the G6 because it is safe, minimally invasive, non-incisional, repeatable and durable. Moreover, the G6 provides physicians and the healthcare system a cost-effective solution for the treatment of glaucoma across the full continuum of care – from early stage to late stage glaucoma.

"We believe these tangible reasons are driving increased awareness and excitement in the worldwide glaucoma community for our G6. We look forward to continued success accelerating CYCLO G6 adoption and utilization,” concluded Moore.


IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the Company’s strategic priorities, market opportunity in Korea, marketing and launch strategy, and plans to accelerate CYCLO G6 adoption and utilization. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors, including the Company’s ability to execute on its strategic goals and market adoption of its products. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Media Contact:

Jamie Hall
Pascale Communications, LLC.

Investor Relations Contact:

Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404

Posted in: News
Actions: E-mail | Permalink |